对阿舍尔综合征,2A型的AAV介导的外因子跳转疗法
Stephanie A Mauriac1, Jiyoon Lee1, Jingyuan Zhang1
1Department of Otolaryngology, F.M Kirby Neurobiology Center, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Molecular therapy : the journal of the American Society of Gene Therapy
|September 25, 2025
概括
使用矢量化反感性寡核酸 (ASO) 的新基因疗法策略显示,它对治疗阿舍尔综合征2A型 (USH2A) 的治疗具有前途. 这种方法旨在通过单次局部注射来纠正最常见的USH2A基因突变来恢复视力和听力.
科学领域:
- 遗传学 是一个遗传学.
- 眼科医生 眼科 眼科
- 耳鼻喉科 耳鼻喉科 耳鼻喉科
背景情况:
- 阿舍尔综合征导致视力,听力和平衡丧失,USH2A突变是全世界最常见的.
- 频繁发生的USH2A c.2299delG突变导致阿舍尔综合征,目前通过需要重复注射的试验性反感 oligonucleotides (ASOs) 进行管理.
- 目前对USH2A的ASO治疗可能需要重复使用才能持续有效.
研究的目的:
- 为USH2A开发一个矢量化的ASO外跳转策略.
- 为了克服长期ASO疗效的重复注射的限制.
- 为USH2A患者创造一种潜在的一次性局部治疗.
主要方法:
- 对USH2A外13船长和腺相关病毒 (AAV) 查.
- 开发优化的矢量化ASO结构.
- 在具有USH2A c.2299delG突变的人类干细胞衍生的内耳和视网膜器官中进行评估.
主要成果:
- 获得了致病性USH2A外原体的增强跳转.
- 优化载体和船长在有机体模型中证明了有效性.
- 矢量化ASO策略显示了阿舍尔综合征治疗的潜力.
结论:
- 矢量化的ASO外子跳转策略为USH2A治疗提供了一个有希望的替代方案.
- 这种方法可能使单次局部注射能够防止视力和听力损失的进展.
- 进一步开发可能会为阿舍尔综合征患者带来一种新的治疗选择.
相关概念视频
Gene Therapy
27.3K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.3K
Alternative RNA Splicing
24.7K
Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
24.7K
Long-patch Base Excision Repair
7.9K
Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
7.9K
RNA Editing
9.8K
RNA editing is a post-transcriptional modification where a precursor mRNA (pre-mRNA) nucleotide sequence is changed by base insertion, deletion, or modification. The extent of RNA editing varies from a few hundred bases, in mitochondrial DNA of trypanosomes, to a just single base, in nuclear genes of mammals. Even a single base change in the pre-mRNA can convert a codon for one amino acid into the codon for another amino acid or a stop codon. This type of re-coding can significantly affect the...
9.8K
RNA Splicing
60.4K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
60.4K


